Cellceutix starts Kevetrin production for clinical trials
Cellceutix’s lead compound Kevetrin is indicated for the treatment of drug-resistant cancers. The company is currently finalizing and reviewing all investigational new drug (IND) documentation for submission to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.